Bifogade filer
Kurs & Likviditet
Kalender
2024-11-21 | Kvartalsrapport 2024-Q3 |
2024-08-22 | Kvartalsrapport 2024-Q2 |
2024-05-16 | Ordinarie utdelning WNT 0.00 SEK |
2024-05-15 | Årsstämma 2024 |
2024-05-03 | Kvartalsrapport 2024-Q1 |
2024-02-29 | Bokslutskommuniké 2023 |
2023-11-16 | Kvartalsrapport 2023-Q3 |
2023-08-17 | Kvartalsrapport 2023-Q2 |
2023-06-02 | Ordinarie utdelning WNT 0.00 SEK |
2023-05-11 | Årsstämma 2023 |
2023-05-04 | Kvartalsrapport 2023-Q1 |
2023-02-09 | Bokslutskommuniké 2022 |
2022-12-12 | Extra Bolagsstämma 2022 |
2022-11-17 | Kvartalsrapport 2022-Q3 |
2022-08-18 | Kvartalsrapport 2022-Q2 |
2022-06-02 | Årsstämma 2022 |
2022-05-06 | Ordinarie utdelning WNT 0.00 SEK |
2022-05-05 | Kvartalsrapport 2022-Q1 |
2022-02-09 | Bokslutskommuniké 2021 |
2021-11-18 | Kvartalsrapport 2021-Q3 |
2021-08-19 | Kvartalsrapport 2021-Q2 |
2021-05-07 | Ordinarie utdelning WNT 0.00 SEK |
2021-05-06 | Kvartalsrapport 2021-Q1 |
2021-05-06 | Årsstämma 2021 |
2021-03-10 | Extra Bolagsstämma 2021 |
2021-02-08 | Bokslutskommuniké 2020 |
2020-11-12 | Kvartalsrapport 2020-Q3 |
2020-08-13 | Kvartalsrapport 2020-Q2 |
2020-06-09 | Ordinarie utdelning WNT 0.00 SEK |
2020-06-08 | Årsstämma 2020 |
2020-05-19 | Kvartalsrapport 2020-Q1 |
2020-04-15 | Extra Bolagsstämma 2020 |
2020-02-20 | Bokslutskommuniké 2019 |
2019-11-14 | Kvartalsrapport 2019-Q3 |
2019-08-15 | Kvartalsrapport 2019-Q2 |
2019-06-14 | Årsstämma 2019 |
2019-05-31 | Kvartalsrapport 2019-Q1 |
2019-05-15 | Ordinarie utdelning WNT 0.00 SEK |
2019-03-19 | Extra Bolagsstämma 2019 |
2019-02-21 | Bokslutskommuniké 2018 |
2018-11-15 | Kvartalsrapport 2018-Q3 |
2018-08-16 | Kvartalsrapport 2018-Q2 |
2018-05-17 | Kvartalsrapport 2018-Q1 |
2018-05-16 | Ordinarie utdelning WNT 0.00 SEK |
2018-05-15 | Årsstämma 2018 |
2018-02-22 | Bokslutskommuniké 2017 |
2017-11-16 | Kvartalsrapport 2017-Q3 |
2017-09-20 | Extra Bolagsstämma 2017 |
2017-08-17 | Kvartalsrapport 2017-Q2 |
2017-05-19 | Ordinarie utdelning WNT 0.00 SEK |
2017-05-18 | Årsstämma 2017 |
2017-05-18 | Kvartalsrapport 2017-Q1 |
2017-02-24 | Bokslutskommuniké 2016 |
2016-11-25 | Kvartalsrapport 2016-Q3 |
2016-08-26 | Kvartalsrapport 2016-Q2 |
2016-05-30 | Ordinarie utdelning WNT 0.00 SEK |
2016-05-27 | Kvartalsrapport 2016-Q1 |
2016-05-27 | Årsstämma 2016 |
2016-02-29 | Bokslutskommuniké 2015 |
2015-11-27 | Kvartalsrapport 2015-Q3 |
2015-08-28 | Kvartalsrapport 2015-Q2 |
2015-06-10 | Ordinarie utdelning WNT 0.00 SEK |
2015-06-09 | Årsstämma 2015 |
2015-05-29 | Kvartalsrapport 2015-Q1 |
2015-02-27 | Bokslutskommuniké 2014 |
2014-11-28 | Kvartalsrapport 2014-Q3 |
2014-08-29 | Kvartalsrapport 2014-Q2 |
2014-06-12 | Ordinarie utdelning WNT 0.00 SEK |
2014-06-11 | Årsstämma 2014 |
2014-05-30 | Kvartalsrapport 2014-Q1 |
2014-04-23 | Analytiker möte 2014 |
2014-02-28 | Bokslutskommuniké 2013 |
2013-11-29 | Kvartalsrapport 2013-Q3 |
2013-08-30 | Kvartalsrapport 2013-Q2 |
2013-06-19 | Ordinarie utdelning WNT 0.00 SEK |
2013-06-18 | Årsstämma 2013 |
2013-05-31 | Kvartalsrapport 2013-Q1 |
2013-03-19 | Analytiker möte 2013 |
2013-02-25 | Bokslutskommuniké 2012 |
2013-02-25 | Extra Bolagsstämma 2013 |
2012-11-13 | 15-7 2012 |
2012-10-19 | Kvartalsrapport 2012-Q3 |
2012-10-18 | Extra Bolagsstämma 2012 |
2012-08-31 | Kvartalsrapport 2012-Q2 |
2012-06-21 | Ordinarie utdelning WNT 0.00 SEK |
2012-06-20 | Årsstämma 2012 |
2012-05-31 | Kvartalsrapport 2012-Q1 |
2012-05-30 | Kvartalsrapport 2012-Q1 |
2012-02-28 | Bokslutskommuniké 2011 |
2011-11-25 | Extra Bolagsstämma 2011 |
2011-11-10 | Kvartalsrapport 2011-Q3 |
2011-08-31 | Kvartalsrapport 2011-Q2 |
2011-06-20 | Ordinarie utdelning WNT 0.00 SEK |
2011-06-17 | Årsstämma 2011 |
2011-05-17 | Kvartalsrapport 2011-Q1 |
2011-02-28 | Bokslutskommuniké 2010 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
Anders Tidfors has a strong background including several CFO assignments, both nationally and internationally. With considerable experience from leading financial roles, Tidfors will strengthen WntResearch in executing the Company's clinical programs with the drug candidate Foxy-5. Tidfors will take up appointment in mid-November, initially combining part-time work for WntResearch with other assignments, including work for a listed company.
"I look forward to continue to develop WntResearch's organization, financial control and positioning together with Anders to implement the company's ongoing development program with Foxy-5 in an effective manner. With an intense and challenging period ahead of us, is it most gratifying to be able to welcome Anders to WntResearch," says acting CEO Anders Rabbe.
For more information, please contact:
Anders Rabbe, Acting CEO, WntResearch AB
E-mail: anders.rabbe@wntresearch.com
Telephone: +46 707 646500
About WntResearch
WntResearch is a research and development company in oncology that develops new treatments intended to inhibit metastasis formation in cancers. The Company focuses on WNT5A, a protein that suppresses the metastatic process in the body; the vision is for cancer patients to no longer have to endure metastasis. Today, one in every three people will develop cancer during their lifetimes, and 90 percent of all cancer-related deaths are caused by metastases. Even though cancer treatment has become more effective, there are no effective methods to prevent the formation of metastasis. The drug candidate Foxy-5 mimics WNT5A' s ability to reduce the mobility and thus the spread of cancer cells. Foxy-5 has demonstrated a good safety profile with few adverse effects in two clinical phase I studies. An ongoing clinical phase II study is currently being conducted on patients with colon cancer with the Company's drug candidate Foxy-5. According to the Company's assessment, Foxy-5 is the only drug candidate of its kind, with a unique mode of action in an area where other drug or treatment options are lacking. WntResearch's share is listed on Spotlight Stock Market. For more information, please visit: www.wntresearch.com